Aaron Davis

Aaron Davis is Co-Founder and Chief Executive Officer of Boxer Capital, LLC. In 2005, after joining Tavistock Group as Portfolio Manager, Mr. Davis scaled Tavistock Group’s public healthcare investing activities and formed Boxer Capital. Mr. Davis leads the firm’s research team, deal structuring, and portfolio management.

Mr. Davis also serves as Chief Executive Officer and a director of BCTG Acquisition Corp., a special purpose acquisition company sponsored by Boxer Capital. He is currently Chairman of the Board of CiVi Biopharma and is a Member of the Board of Directors of iTeos Therapeutics (NASDAQ: ITOS), Mirati Therapeutics (NASDAQ: MRTX), and Odonate Therapeutics (NASDAQ: ODT).

Prior to joining Tavistock Group, Mr. Davis worked in the Global Healthcare Investment Banking and Private Equity Group at UBS Warburg, LLC. During this period, Mr. Davis led strategic transactions for public and private biotechnology and medical device companies throughout their growth, advising on financing and mergers and acquisitions. Having also served in various roles with biotechnology and venture capital firms, Mr. Davis has extensive expertise in investment analysis and in overseeing in-licensing activities within the pharmaceutical sector.

Mr. Davis holds a Master of Science in Biotechnology from Columbia University and a Bachelor of Arts in Business Administration from Emory University.